BKYI - Bio-key International Inc Stock Price, Fair Value and News

1.64USD-0.02 (-1.20%)Market Closed

Market Summary

USD1.64-0.02

Market Closed

-1.20%

BKYI Stock Price

View Fullscreen

BKYI RSI Chart

BKYI Valuation

Market Cap

22.5M

Price/Earnings (Trailing)

-2.75

Price/Sales (Trailing)

2.93

EV/EBITDA

-2.29

Price/Free Cashflow

-5.96

BKYI Price/Sales (Trailing)

BKYI Profitability

Operating Margin

62.25%

EBT Margin

-129.59%

Return on Equity

-275.7%

Return on Assets

-93.73%

Free Cashflow Yield

-16.77%

BKYI Fundamentals

BKYI Revenue

Revenue (TTM)

8.6M

Rev. Growth (Yr)

32.29%

Rev. Growth (Qtr)

-5.8%

BKYI Earnings

Earnings (TTM)

-9.1M

Earnings Growth (Yr)

73.45%

Earnings Growth (Qtr)

55.17%

Breaking Down BKYI Revenue

Last 7 days

-10.4%

Last 30 days

-19.2%

Last 90 days

-17.6%

Trailing 12 Months

111.9%

How does BKYI drawdown profile look like?

BKYI Financial Health

Current Ratio

1.3

Debt/Equity

0.07

Debt/Cashflow

-18.78

BKYI Investor Care

Shares Dilution (1Y)

62.21%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	8.2M	8.1M	8.6M	0
2022	5.2M	6.1M	6.2M	7.0M
2021	4.2M	4.9M	5.2M	5.1M
2020	2.2M	1.8M	2.3M	2.8M
2019	3.8M	3.7M	3.4M	2.3M
2018	5.7M	5.6M	5.4M	4.0M
2017	4.0M	4.4M	4.9M	6.3M
2016	5.0M	3.2M	2.9M	3.0M
2015	3.3M	5.2M	4.5M	5.3M
2014	2.5M	2.5M	3.4M	4.0M
2013	3.7M	3.6M	3.6M	2.0M
2012	3.5M	3.1M	2.9M	4.3M
2011	3.5M	3.5M	3.5M	3.5M
2010	0	0	0	3.5M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Bio-key International Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 27, 2024	alia emmanuel	acquired	-	-	1,429	-
Mar 27, 2024	michel robert j	acquired	-	-	1,429	-
Mar 27, 2024	williams cameron e.	acquired	-	-	1,429	-
Dec 29, 2023	depasquale michael w	acquired	354	2.55	139	chief executive officer
Dec 29, 2023	lacous mira k	acquired	354	2.55	139	chief technology officer
Dec 29, 2023	sullivan james david	acquired	354	2.55	139	chief legal officer
Dec 01, 2023	depasquale michael w	bought	3,600	0.18	20,000	chief executive officer
Nov 30, 2023	sullivan james david	bought	3,300	0.165	20,000	chief legal officer
Nov 27, 2023	sullivan james david	bought	1,643	0.164319	10,003	chief legal officer
Nov 24, 2023	sullivan james david	bought	4,861	0.163874	29,668	chief legal officer

Which funds bought or sold BKYI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-59,089	-	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	new	-	1,002	1,002	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	sold off	-100	-13,058	-	-%
Feb 13, 2024	RENAISSANCE TECHNOLOGIES LLC	sold off	-100	-6,000	-	-%
Feb 13, 2024	NORTHERN TRUST CORP	sold off	-100	-5,792	-	-%
Feb 13, 2024	Abich Financial Wealth Management LLC	new	-	111	111	-%
Feb 13, 2024	NewEdge Advisors, LLC	sold off	-100	-31.00	-	-%
Feb 13, 2024	NewEdge Advisors, LLC	new	-	12.00	12.00	-%
Feb 13, 2024	ARMISTICE CAPITAL, LLC	new	-	196,002	196,002	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-1,586	-	-%

Are Funds Buying or Selling BKYI?

Are funds buying BKYI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BKYI

No. of Funds

Unveiling Bio-key International Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	121,494	SC 13G
Feb 13, 2024	lind global fund ii lp	4.7%	46,285	SC 13G/A
Jan 25, 2024	ajb capital investments llc	3.4%	26,137	SC 13G/A
Jan 10, 2023	ajb capital investments llc	8.3%	7e+05	SC 13G
Feb 11, 2022	lind global macro fund lp	9.6%	833,125	SC 13G/A
Feb 09, 2021	lind global macro fund lp	9.6%	833,126	SC 13G/A
Aug 03, 2020	intracoastal capital, llc	4.2%	2,250,000	SC 13G
Apr 08, 2020	lind global macro fund lp	5.9%	855,633	SC 13G

Recent SEC filings of Bio-key International Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	8-K	Current Report
Apr 02, 2024	NT 10-K	NT 10-K
Apr 02, 2024	8-K	Current Report
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading
Feb 16, 2024	424B3	Prospectus Filed
Feb 14, 2024	SC 13G	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 12, 2024	EFFECT	EFFECT

Peers (Alternatives to Bio-key International Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ADP	101.4B	18.6B	-0.31%	14.56%	28.5	5.46	7.76%	13.08%
CTAS	67.6B	9.4B	4.21%	45.50%	44.97	7.18	9.34%	15.98%
CPRT	52.2B	4.1B	-5.42%	38.27%	38.49	12.86	10.52%	25.37%
EFX	27.7B	5.4B	-15.03%	11.71%	49.74	5.18	5.76%	-4.95%
BAH	18.9B	10.3B	-1.12%	51.29%	46.26	1.83	13.90%	-5.05%
ALLE	11.1B	3.7B	-5.34%	23.09%	20.57	3.04	11.58%	17.98%
MID-CAP
RHI	7.5B	6.4B	-10.08%	-1.85%	18.3	1.18	-11.68%	-37.51%
AL	5.7B	2.7B	5.63%	30.86%	9.21	2.11	15.87%	733.47%
SRCL	4.7B	2.7B	-3.97%	19.05%	-218.64	1.75	-1.68%	-137.70%
ABM	2.8B	8.2B	2.27%	6.00%	10.98	0.35	3.98%	33.49%
SMALL-CAP
AZZ	1.9B	2.7B	6.33%	110.13%	21.53	0.69	104.63%	175.67%
ALTG	385.8M	1.9B	-7.84%	-16.60%	43.35	0.21	19.40%	-4.30%
ARC	115.5M	281.2M	1.12%	-11.48%	14.02	0.41	-1.68%	-25.77%
AQMS	58.2M	1.1M	8.33%	-54.78%	-2.43	49.78	336.95%	-55.13%
AWX	8.8M	80.5M	-6.61%	-18.12%	-4.9	0.11	-0.82%	-207.00%

Bio-key International Inc News

Latest updates

Bio-key International Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-5.8%	1,817,108	1,928,929	3,083,767	1,758,423	1,373,549	1,947,115	1,941,171	934,932	1,298,829	992,090	1,888,638	1,063,830	943,325	307,142	522,485	534,808	452,714	728,383	551,623	1,715,196	739,750
Gross Profit	1.3%	1,340,504	1,322,818	2,263,493	774,030	979,766	1,223,162	1,603,730	562,881	1,004,155	752,521	1,122,003	753,330	731,716	158,688	398,222	-134,308	-55,939	48,957	-52,427	700,586	-200,582
Operating Expenses	-15.8%	2,106,062	2,501,345	2,621,891	5,770,184	3,340,212	2,790,656	2,603,264	2,562,200	1,998,131	1,865,036	1,958,049	2,174,880	1,821,454	1,530,501	1,718,288	-	1,215,198	1,359,888	1,751,151	2,080,705	1,440,777
S&GA Expenses	-20.4%	1,547,376	1,943,164	1,931,732	3,049,610	2,510,706	2,006,573	1,797,998	1,752,344	1,385,534	1,374,084	1,516,398	1,765,119	1,490,241	1,211,928	1,381,399	1,686,050	915,066	1,058,671	1,377,033	1,746,598	1,049,270
R&D Expenses	0.1%	558,686	558,181	690,159	833,381	829,506	784,083	805,266	809,856	612,597	490,952	441,651	409,761	331,213	318,573	336,889	356,201	300,132	301,217	374,118	334,107	391,507
EBITDA Margin	12.0%	-1.27	-1.44	-1.45	-1.69	0.01	0.01	0.01	0.02	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-19.6%	45,655	56,806	56,919	6,851	2,071	1,540	-	9,000	-	-	18,000	19,635	2,204,920	567,516	1,551,141	395,784	558,449	114,866	70.00	16.00	44.00
Income Taxes	-100.1%	-189	143,000	-	20,434	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	50.2%	-638,013	-1,279,878	-	-6,809,468	-2,402,509	-1,718,957	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	11.5%	-1.30	-1.46	-1.46	-1.70	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	55.2%	-637,824	-1,422,878	-288,322	-6,789,034	-2,402,509	-1,718,957	-999,403	-2,029,020	-1,023,647	-1,161,683	-851,431	-1,437,444	-3,293,552	-1,572,709	-3,370,282	-9,529,882	-1,829,567	-1,425,743	-1,803,508	-1,380,103	-1,641,315
Net Income Margin	20.5%	-1.06	-1.34	-1.37	-1.70	-1.15	-0.94	-1.01	-0.99	-0.85	-1.38	-1.70	-3.41	-7.70	-	-	-	-	-	-	-	-
Free Cashflow	-0.2%	-166,730	-166,381	-1,928,811	-1,951,605	-2,049,135	-871,500	-1,438,834	-1,874,447	-1,887,828	-2,046,311	-3,211,866	-1,293,513	-1,719,034	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	-7.9%	9,749	10,583	11,106	11,344	15,026	17,625	19,403	17,769	20,728	20,944	21,483	22,521	24,001	5,752	3,019	2,497	10,782	11,156	11,263	11,692	13,002
Current Assets	-8.3%	7,820	8,531	8,936	8,985	9,883	12,349	13,806	14,013	16,772	17,292	17,730	18,942	20,366	2,285	1,990	1,366	3,694	3,814	3,557	4,229	5,910
Cash Equivalents	-45.7%	307	566	722	2,636	2,775	4,893	5,801	7,754	9,592	11,480	13,529	16,993	18,396	887	662	79.00	78.00	687	459	324	1,049
Inventory	-2.2%	4,289	4,384	4,428	4,434	4,893	4,889	4,956	4,941	4,635	2,291	600	331	399	389	389	429	971	1,012	981	999	1,044
Net PPE	-14.6%	69.00	81.00	94.00	107	126	135	129	69.00	71.00	60.00	70.00	82.00	79.00	96.00	76.00	96.00	118	137	153	149	170
Goodwill	-	-	-	-	-	2,198	2,256	1,721	1,263	1,263	1,263	1,263	1,263	1,155	1,263	-	-	-	-	-	-	-
Liabilities	-4.5%	6,435	6,738	5,949	6,043	3,828	4,005	4,021	2,154	3,195	2,445	1,861	2,185	2,318	4,970	4,430	4,782	3,663	3,082	2,074	1,226	1,211
Current Liabilities	-4.0%	6,028	6,276	5,425	5,456	3,344	3,533	3,488	1,999	3,014	2,211	1,600	1,876	1,952	4,623	4,077	4,391	3,236	2,699	1,655	1,226	1,211
Short Term Borrowings	-6.7%	2,331	2,499	2,454	2,596	-	-	-	-	-	-	-	232	235	500	-	-	-	-	-	-	-
Long Term Debt	-13.2%	222	255	278	327	322	379	424	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	0%	135	135	135	120	120	122	123	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-13.2%	222	255	278	327	322	379	424	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-13.8%	3,314	3,845	5,157	5,302	11,199	13,620	15,382	15,615	17,533	18,499	19,622	20,335	21,682	782	-	-	7,119	8,074	9,189	10,466	11,791
Retained Earnings	-0.5%	-118,834	-118,196	-116,773	-116,485	-109,696	-107,293	-105,574	-104,575	-102,546	-101,522	-100,361	-99,509	-98,072	-94,778	-93,205	-89,723	-80,193	-78,363	-76,937	-75,134	-73,754
Additional Paid-In Capital	0.1%	122,263	122,191	122,100	122,029	121,123	121,023	120,900	120,190	120,079	120,021	119,982	119,844	119,748	95,559	91,793	87,438	87,311	86,436	86,125	85,599	85,544
Shares Outstanding	2.6%	9,502	9,263	9,226	9,191	8,054	8,098	7,885	7,854	7,789	7,776	7,774	7,815	6,436	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	13,509	-	-	-	27,600	-	-	-	15,700	-	-	-	8,200	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	-0.2%	-166	-166	-1,928	-1,900	-2,040	-853	-1,434	-1,870	-1,865	-2,043	-3,198	-1,264	-1,716	-946	-1,022	29.00	-1,622	-416	160	-695	-1,016
Share Based Compensation	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	510	77.00	189
Cashflow From Investing	-	-	-	-	-130	-6.18	-14.43	-545	-4.14	-22.18	-2.39	-13.31	-26.17	-297	-	-	-	-512	-5.36	-25.13	-315*	-13.66
Cashflow From Financing	-936.1%	-83.08	-8.02	-34.29	1,864	-	39.00	-	37.00	-	-2.52	-252	-206	19,523	3,078	1,606	-28.09	1,527	-	-	-28.86	1,775

BKYI Income Statement

2023-09-30

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues
Revenues	$ 1,817,108	$ 1,373,549	$ 6,829,804	$ 5,261,835
Costs and other expenses
Costs and other expenses	476,604	393,783	1,902,989	1,455,177
Gross profit	1,340,504	979,766	4,926,815	3,806,658
Operating Expenses
Selling, general and administrative	1,547,376	2,510,706	5,422,272	6,315,277
Research, development and engineering	558,686	829,506	1,807,026	2,418,855
Total Operating Expenses	2,106,062	3,340,212	7,229,298	8,734,132
Operating loss	(765,558)	(2,360,446)	(2,302,483)	(4,927,474)
Other income (expense)
Interest income	5,917	8	5,944	216
Loss on foreign currency transactions	0	0	(15,000)	0
Investment-debt security reserve	0	(40,000)	0	(190,000)
Change in fair value of convertible note	167,283	0	264,706	0
Interest expense	(45,655)	(2,071)	(159,379)	(3,611)
Total other income (expense), net	127,545	(42,063)	96,271	(193,395)
Loss before provision for income tax	(638,013)	(2,402,509)	(2,206,212)	(5,120,869)
Provision for (income tax) tax benefit	189	0	(142,811)	0
Net loss	(637,824)	(2,402,509)	(2,349,023)	(5,120,869)
Comprehensive loss:
Net loss	(637,824)	(2,402,509)	(2,349,023)	(5,120,869)
Other comprehensive income (loss) – Foreign currency translation adjustment	35,364	(119,269)	127,394	(229,350)
Comprehensive loss	$ (602,460)	$ (2,521,778)	$ (2,221,629)	$ (5,350,219)
Basic and Diluted Loss per Common Share (in dollars per share)	$ (0.07)	$ (0.29)	$ (0.26)	$ (0.64)
Weighted Average Common Shares Outstanding:
Basic and diluted (in shares)	9,081,873	8,148,848	9,042,319	8,054,207
Service [Member]
Revenues
Revenues	$ 587,893	$ 371,956	$ 1,740,880	$ 1,202,866
Costs and other expenses
Costs and other expenses	125,039	162,632	639,996	554,222
License [Member]
Revenues
Revenues	950,015	918,260	4,664,341	3,540,592
Costs and other expenses
Costs and other expenses	203,891	173,310	1,022,919	604,677
Hardware [Member]
Revenues
Revenues	279,200	83,333	424,583	518,377
Costs and other expenses
Costs and other expenses	$ 147,674	$ 57,841	$ 240,074	$ 296,278

BKYI Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
ASSETS
Cash and cash equivalents	$ 307,086	$ 2,635,522
Accounts receivable, net	2,799,218	1,522,784
Due from factor	62,572	49,500
Inventory	4,289,213	4,434,369
Prepaid expenses and other	362,250	342,706
Total current assets	7,820,339	8,984,881
Equipment and leasehold improvements, net	69,202	107,413
Capitalized contract costs, net	264,348	283,069
Deposits and other assets	0	8,712
Deferred offering costs	25,434	0
Operating lease right-of-use assets	50,465	197,355
Intangible assets, net	1,519,592	1,762,825
Total non-current assets	1,929,041	2,359,374
TOTAL ASSETS	9,749,380	11,344,255
LIABILITIES
Accounts payable	1,656,107	1,108,279
Accrued liabilities	1,080,032	1,009,123
Income taxes payable	162,811	0
Convertible note payable	2,331,497	2,596,203
Government loan – BBVA Bank, current portion	135,308	120,000
Deferred revenue, current	610,451	462,418
Operating lease liabilities, current portion	51,746	159,665
Total current liabilities	6,027,952	5,455,688
Deferred revenue, long term	32,354	52,134
Deferred tax liability	152,998	170,281
Government loan – BBVA Bank – net of current portion	221,625	326,767
Operating lease liabilities, net of current portion	0	37,829
Total non-current liabilities	406,977	587,011
TOTAL LIABILITIES	6,434,929	6,042,699
Commitments and Contingencies
STOCKHOLDERS’ EQUITY
Common stock — authorized, 170,000,000 shares; issued and outstanding; 9,501,669 and 9,190,504 of $.0001 par value at September 30, 2023 and December 31, 2022, respectively	950	919
Additional paid-in capital	122,263,106	122,028,612
Accumulated other comprehensive loss	(115,208)	(242,602)
Accumulated deficit	(118,834,397)	(116,485,373)
TOTAL STOCKHOLDERS’ EQUITY	3,314,451	5,301,556
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 9,749,380	$ 11,344,255

About Bio-key International Inc

BIO-key International, Inc. develops and markets fingerprint identification biometric technology and software solutions, and enterprise-ready identity access management solutions for commercial, government, and education customers in the United States and internationally. The company offers BIO-key PortalGuard and PortalGuard IDaaS solutions, a customer-controlled and neutral-by-design cloud-based identity platform that allows customers to integrate with any cloud or on-premises SaaS application, as well as windows device authentication through IAM platform. Its solutions enable its customers to secure their workforces and student populations; and make their partner networks more collaborative. In addition, it provides BIO-key VST and WEB-key products; and Civil and Large-Scale ID Infrastructure solutions that develops finger-based biometric technology. Further, it offers finger scanners for enterprise and consumer markets under SideSwipe, EcoID, and SidePass brand names. The company was formerly known as SAC Technologies and changed its name to BIO-key International, Inc. in 2002. BIO-key International, Inc. was founded in 1993 and is headquartered in Wall, New Jersey.

CEO	Mr. Michael W. DePasquale
WEBSITE	bio-key.com
INDUSTRY	Information Technology Services
EMPLOYEES	51

Bio-key International Inc Frequently Asked Questions

What is the ticker symbol for Bio-key International Inc? What does BKYI stand for in stocks?

BKYI is the stock ticker symbol of Bio-key International Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bio-key International Inc (BKYI)?

As of Tue Apr 23 2024, market cap of Bio-key International Inc is 22.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BKYI stock?

You can check BKYI's fair value in chart for subscribers.

What is the fair value of BKYI stock?

You can check BKYI's fair value in chart for subscribers. The fair value of Bio-key International Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bio-key International Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BKYI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bio-key International Inc a good stock to buy?

The fair value guage provides a quick view whether BKYI is over valued or under valued. Whether Bio-key International Inc is cheap or expensive depends on the assumptions which impact Bio-key International Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BKYI.

What is Bio-key International Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, BKYI's PE ratio (Price to Earnings) is -2.75 and Price to Sales (PS) ratio is 2.93. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BKYI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Bio-key International Inc's stock?

In the past 10 years, Bio-key International Inc has provided 0.021 (multiply by 100 for percentage) rate of return.